Literature DB >> 3138056

Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo.

D J Greenblatt1, J S Harmatz, C Dorsey, R I Shader.   

Abstract

Thirty-nine healthy volunteers received single oral doses of either alprazolam (1 mg), lorazepam (2 mg), prazepam (20 mg), or placebo in a randomized, double-blind, parallel group study. Plasma drug concentrations, subjective self-ratings, and the digit symbol substitution test (DSST) were evaluated during 24 hours after dosage. Alprazolam was absorbed rapidly and produced correspondingly rapid sedation and impaired DSST performance. These effects also resolved rapidly, being similar to placebo by 4 to 6 hours after dosage. Sedative and DSST-impairing effects of lorazepam were of slower onset but longer duration than those of alprazolam. After oral prazepam, appearance of desmethyldiazepam in plasma was slow, with minimal sedative and DSST-impairing effects. Twenty-four hours after dosage, both alprazolam and lorazepam significantly impaired recall of a list of 16 words learned previously 3 hours after dosage. Thus benzodiazepines with approximately equivalent clinical anxiolytic properties may have different sedative, performance-impairing, and amnesic profiles after single doses in healthy volunteers; these differences are explained at least in part by pharmacokinetic variations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3138056     DOI: 10.1038/clpt.1988.158

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  Pharmacokinetic-pharmacodynamic analysis of mnesic effects of lorazepam in healthy volunteers.

Authors:  O Blin; A Jacquet; S Callamand; E Jouve; M Habib; D Gayraud; A Durand; B Bruguerolle; P Pisano
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state.

Authors:  J M Scavone; D J Greenblatt; J E Goddard; H Friedman; J S Harmatz; R I Shader
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

4.  Amygdala abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine challenge.

Authors:  Daniel H Wolf; Theodore D Satterthwaite; James Loughead; Amy Pinkham; Eve Overton; Mark A Elliott; Gersham W Dent; Mark A Smith; Ruben C Gur; Raquel E Gur
Journal:  Psychopharmacology (Berl)       Date:  2011-05-21       Impact factor: 4.530

Review 5.  A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs.

Authors:  Cara Tannenbaum; Amélie Paquette; Sarah Hilmer; Jayna Holroyd-Leduc; Ryan Carnahan
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

6.  Lorazepam dose-dependently decreases risk-taking related activation in limbic areas.

Authors:  Estibaliz Arce; Daniel A Miller; Justin S Feinstein; Murray B Stein; Martin P Paulus
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

7.  Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg.

Authors:  Tim R M Leufkens; Annemiek Vermeeren; Beitske E Smink; Peter van Ruitenbeek; Johannes G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2007-01-12       Impact factor: 4.530

8.  The effects of repeated doses of clomipramine and alprazolam on physiological, psychomotor and cognitive functions in normal subjects.

Authors:  D Allen; H V Curran; M Lader
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Characterization of cognitive dysfunction in Sjögren's syndrome patients.

Authors:  Lynn C Epstein; Gina Masse; Jerold S Harmatz; Tammy M Scott; Athena S Papas; David J Greenblatt
Journal:  Clin Rheumatol       Date:  2013-12-15       Impact factor: 2.980

10.  Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II. Triazolam.

Authors:  S K Gupta; E H Ellinwood; A M Nikaido; D G Heatherly
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.